Highlights from the 79th Scientific Sessions of the American Diabetes Association

American Diabetes Association, 79th Scientific Sessions, 2019. Final Program. https://professional.diabetes.org/sites/professional.diabetes.org/files/media/79th_scientific_sessions_final_program.pdf

Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or pre-diabetes: a consensus report. Diabetes Care 2019; 42:731–54. https://doi.org/10.2337/dci19-0014

American Diabetes Association, 79th Scientific Sessions, 2019. Abstracts. Diabetes 2019;68 (Suppl 1). https://diabetes.diabetesjournals.org/content/68/Supplement_1

American Diabetes Association. ePosters. https://ada.scientificposters.com/epsWelcome.cfm

American Diabetes Association. 79th Scientific Sessions Webcasts 2019. https://professional.diabetes.org/webcasts-ss2019

Pittas AG, Dawson-Hughes B, Sheehan P, et al and the D2d Research Group. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med 2019;381:520–30. https://doi.org/10.1056/NEJMoa1900906

Zhyhneuskaya SV, Al-Mrabeh A, Barnes AC, et al. Remission of type 2 diabetes for two years is associated with full recovery of beta-cell functional mass in the diabetes remission clinical trial (DiRECT). Diabetes 2019;68(Suppl 1):Abs 66-OR. https://doi.org/10.2337/db19-66-OR

Chen Y, Zhang P, Wang J, et al. Early progression to diabetes or regression to normal glucose tolerance among people with impaired glucose tolerance affects long-term outcomes: thirty-year follow-up of Da Qing Diabetes Prevention Study. Diabetes 2019;68(Suppl 1):Abs 153-OR. https://doi.org/10.2337/db19-153-OR

The RISE Consortium. Lack of durable improvements in β-cell function following withdrawal of pharmacological interventions in adults with impaired glucose tolerance or recently diagnosed type 2 diabetes. Diabetes Care 2019;42:1742–51. https://doi.org/10.2337/dc19-0556

The RISE Consortium. Effects of treatment of impaired glucose tolerance or recently diagnosed type 2 diabetes with metformin alone or in combination with insulin glargine on β-cell function: comparison of responses in youth and adults. Diabetes 2019;68:1670–80. https://doi.org/10.2337/db19-0299

Rosenstock J, Kahn SE, Johansen OD, et al for the CAROLINA investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The CAROLINA randomized clinical trial. JAMA 2019;322:1155-66. https://doi.org/10.1001/jama.2019.13772

Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 2019;321:69–79. https://doi.org/10.1001/jama.2018.18269

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019; 394:121–30. https://doi.org/10.1016/S0140-6736(19)31149-3

Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019; 381:841–51. https://doi.org/10.1056/NEJMoa1901118

Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol 2019;7:606–17. https://doi.org/10.1016/S2213-8587(19)30180-9

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–306. https://doi.org/10.1056/NEJMoa1811744

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019;394:131–8. https://doi.org/10.1016/S0140-6736(19)31150-X.